TOTAL: $550.14M | ||||
Company | Location | Date | Amt. (M) | Details |
Accumetrics Inc. | San Diego | 10/6 | $16.5 | Accumetrics completed a round to raise $16.5M from existing investors, including Arnerich Massena, BBT Fund/Apothecary Capital, Essex Woodlands Health Ventures, Kaiser Permanente Ventures and RiverVest Venture Partners |
Adimab Inc. | Lebanon, N.H. | 10/1 | ND | Adimab raised an undisclosed amount of money in its Series D financing round led by Google Ventures and included Polaris Ventures, SV Life Sciences, OrbiMed Advisors and Borealis Ventures |
Arginetix Inc. | Baltimore | 10/2 | $10.75 | Arginetix closed a $10.75M Series A financing co-led by Quaker BioVentures and MedImmune Ventures; other investors were Maryland Health Care Product Development Corp., Osage University Partners, Red Abbey Venture Partners and company co-founder Acifophil LLC |
Axcentua Pharmaceuticals AB | Huddinge, Sweden | 10/8 | ND | Axcentua closed its Series A round led by William Gunnarsson, former CEO and co-founder of Orphan Europe |
Bellicum Pharmaceuticals Inc. | Houston | 10/27 | $4.5 | Bellicum raised $4.5M in a Series A and convertible note funding |
Bicycle Therapeutics Ltd. | London | 10/6 | ND | Bicycle secured seed funding from Atlas Venture and Novartis Venture Fund |
Biocartis SA | Lausanne, Switzerland | 10/15 | $14.9 | Biocartis raised about $14.9M in a Series A round from a syndicate of life science investors led by Aescap Venture |
CBio Ltd. | Brisbane, Australia | 10/9 | A$10 ($9) | CBio completed a $9M financing ahead of a planned share market listing on the Australian Stock Exchange; it was underwritten by Novus Capital Ltd., which acted as financial advisor |
Celtic Therapeutics Holdings LP | St. Thomas, U.S. Virgin Islands | 10/28 | $100 | PPD Inc. signed an agreement to invest $100M in Celtic |
Crescendo Biologics Ltd. | Cambridge, Mass. | 10/12 | £4.5 ($7.12) | Crescendo raised $7.12M in a seed-funding round led by Sofinnova Partners |
Endocyte Inc. | West LaFayette, Ind. | 10/15 | $26 | Completed a $26M extension of its Series C financing, including investments from Sanderling Ventures, Burrill & Co., American Bailey Ventures, Blue Chip Venture Co., and Triathlon Medical Ventures, as well as Clarian Health Ventures |
Envoy Therapeutics Inc. | Jupiter, Fla. | 10/15 | $8 | Envoy Therapeutics raised $8M through a private placement of Series A preferred stock |
Epizyme Inc. | Cambridge, Mass. | 10/7 | $32 | Epizyme raised $32M in a Series B round led by Bay City Capital, with new investments from Amgen Ventures and Astellas Venture Management and participation from existing investors MPM Capital and Kleiner Perkins Caufield and Byers |
Evolva SA | Basel, Switzerland | 10/22 | CHF28($27.8) | Evolva completed a $27.8M Series B round as part of its move to merge with Arpida AG; investors were Aravis, Auriga Partners, Vinci Capital-Renaissance PME and Wellington Partners, as well as BioMedInvest, an undisclosed private investor, Astellas Venture, Dansk Innovation, Novartis Bioventures and Sunstone Capital |
Flexion Therapeutics | Woburn, Mass. | 10/19 | $33 | Flexion completed a $33M Series A financing round |
GlycoMimetics | Gaithersburg, Md. | 10/21 | $38 | GlycoMimetics raised $38M in the round, with investments from Genzyme Ventures, New Enterprise Associates, The Novartis Venture Fund, Anthem Capital and Alliance Technology Ventures |
Inviragen LLC | Fort Collins, Colo. | 10/6 | $15 | Inviragen closed $15M in a Series A financing with investments from Charter Life Sciences, Bio*One Capital, Venture Investors LLC and Phillip Private Equity; it was done concurrently with the company's merger with SingVax Pte Ltd. of Singapore |
Integrated Diagnostics | Seattle | 10/14 | $30 | Integrated Diagnostics raised more than $30M in funding in a Series A led by InterWest Partners; other investors were the Wellcome Trust and dievini Hopp Biotech holding |
Lux Biosciences Inc. | Jersey City, N.J. | 10/19 | $50 | Lux has raised $50M in a Series B round |
Metabolon Inc. | Research Triangle Park, N.C. | 10/27 | $6 | Metabolon closed an additional $6M in its Series C financing round, bringing the total raised to $12.3M; investors were Syngenta Ventures, Fletcher Spaght Ventures, Sevin Rosen Funds, Aurora Funds, Harris and Harris Group, Fulcrum Financial Partners and Alexandria Equities |
Mission Bay Capital LLC | San Francisco | 10/27 | $7.5 | Mission Bay raised $7.5M in its first venture round |
Mtm Laboratories AG | Heidelberg, Germany | 10/5 | €7 ($10.3) | Mtm brought in $10.3M in Series C funding; investors were Gilde Healthcare Partners, HBM BioVentures Ltd., HBM BioCapital Invest Ltd. and LBBW Venture Capital GmbH |
OncoCyte Corp. | Alameda, Calif. | 10/16 | $2 | A private investor put $2M into OncoCyte, a new subsidiary of BioTime Inc. |
PharmaDiagnostics NV | Brussels, Belgium | 10/12 | €2.5 ($3.5) | PharmaDiagnostics secured funding of $3.5M from its initial investors led by venture fund Capital-E |
Pronota NV | Ghent, Belgium | 10/29 | €1.3 ($1.9) |
Pronota raised an additional $1.9M in its Series B round, which was subscribed by MP Healthcare Venture Management Inc. |
Synageva BioPharma Corp. | Waltham, Mass. | 10/20 | $15 | Synageva completed the final closing on a $45M financing that began earlier this year; $30M of the amount was accounted for in April |
Tarsa Therapeutics | Philadelphia | 10/20 | $24 | Tarsa closed on a $24M Series A financing |
Tetraphase Pharmaceuticals Inc. | Watertown, Mass. | 10/6 | $10 | Tetraphase closed the first $10M tranche of a $25M Series B round funded by Mediphase Venture Partners, CMEA Ventures, Fidelity Biosciences, Flagship Ventures and Skyline Ventures |
Virdante Pharmaceuticals Inc. | Cambridge, Mass. | 10/29 | $47 | Virdante raised $47M in a Series A led by Thomas, McNerney & Partners with participation by Osage Partners and Clarus Ventures, Venrock, MedImmune Ventures and Biogen Idec New Ventures |
VitamFero | Evry, France | 10/8 | €0.247 ($0.365) | VitamFero completed its first round, with three founders bringing in $66,540 and 15 business angels from the Val de France Angels group adding $298,460 |
Notes: Currency conversions are based on exchange rates at the time of the deal. ** Denotes the date the item ran in BioWorld International.ND = Not disclosed. | ||||